Blood Res.  2021 Dec;56(4):333-334. 10.5045/br.2021.2020322.

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?

• Cencini E
• Fabbri A
• Raspadori D
• Gozzetti A
• Bocchia M

• KMID: 2524094
• DOI: http://doi.org/10.5045/br.2021.2020322

Reference

1. Göçer M, Kurtoğlu E. 2020; Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Res. 55:206–12. DOI: 10.5045/br.2020.2020158. PMID: 33303706. PMCID: PMC7784134.

2. Zucca E, Arcaini L, Buske C, et al. 2020; Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31:17–29. DOI: 10.1016/j.annonc.2019.10.010. PMID: 31912792.

3. Tessoulin B, Eveillard M, Lok A, et al. 2017; p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell. Blood Rev. 31:251–9. DOI: 10.1016/j.blre.2017.03.001. PMID: 28284458.

4. Noy A, de Vos S, Thieblemont C, et al. 2017; Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 129:2224–32. DOI: 10.1182/blood-2016-10-747345. PMID: 28167659. PMCID: PMC5399483.

5. Noy A, de Vos S, Coleman M, et al. 2020; Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 4:5773–84. DOI: 10.1182/bloodadvances.2020003121. PMID: 33227125. PMCID: PMC7686907.

6. Furqan F, Watson G, Samaniego F, et al. 2020; Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma. 61:2980–4. DOI: 10.1080/10428194.2020.1791849. PMID: 32650677. PMCID: PMC7683361.

7. Lynch RC, Advani RH. 2017; Dramatic response with single-agent ibrutinib in multiply relapsed marginal zone lymphoma with MYD88L265P mutation. Case Rep Oncol. 10:813–8. DOI: 10.1159/000480292. PMID: 29070995. PMCID: PMC5649220.

8. Zhao L, Qu X, Wu Z, Li Y, Zhang X, Guo W. 2020; TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy. Aging (Albany NY). 12:14556–68. DOI: 10.18632/aging.103502. PMID: 32694238. PMCID: PMC7425464.

9. Fang S, Cheng W, Zhang M, Yang R. 2020; Association of TP53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer. Onco Targets Ther. 13:6645–50. DOI: 10.2147/OTT.S257052. PMID: 32753898. PMCID: PMC7354100.

10. Gao W, Wang M, Wang L, et al. 2014; Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 106:dju204. DOI: 10.1093/jnci/dju204. PMID: 25214559. PMCID: PMC4200057.

11. O'Brien S, Furman RR, Coutre S, et al. 2018; Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 131:1910–9. DOI: 10.1182/blood-2017-10-810044. PMID: 29437592. PMCID: PMC5921964.

12. Guarini A, Peragine N, Messina M, et al. 2019; Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. Br J Haematol. 184:392–6. DOI: 10.1111/bjh.15613. PMID: 30338509.

13. Rule S, Dreyling M, Goy A, et al. 2019; Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 104:211–4. DOI: 10.3324/haematol.2018.205229. PMID: 30442728. PMCID: PMC6518912.

14. Flinn IW, Miller CB, Ardeshna KM, et al. 2019; DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 37:912–22. DOI: 10.1200/JCO.18.00915. PMID: 30742566.

15. Eyre TA, Walter HS, Iyengar S, et al. 2019; Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 104:e68–71. DOI: 10.3324/haematol.2018.198812. PMID: 30190341. PMCID: PMC6355471.